Emmaus Life Sciences, Inc. last reported quarterly results on Aug 14, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $6.3 million (+124.3% year over year) and diluted EPS of $0.02. It usually reports 45 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 13, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Friday. Based on last year's release for the same quarter on Nov 14, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 14, 2026
45 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
6
+124.3%
|
1
+218.0%
|
0.02
+200.0%
|
|
May 15, 2026
45 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
-17.6%
|
-3
-43.1%
|
-0.05
-25.0%
|
|
Nov 14, 2025
45 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
-38.3%
|
-2
-213.6%
|
-0.03
-200.0%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
-47.6%
|
-1
+48.0%
|
-0.02
+33.3%
|
|
Apr 14, 2025
14 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
-4.0%
|
-2
+46.4%
|
-0.04
+42.9%
|
|
Nov 19, 2024
50 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
5
+9.2%
|
2
+2626.9%
|
0.03
+400.0%
|
|
Jul 3, 2024
3 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
|
Nov 14, 2023
45 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EMMA (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Torrance, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 822370
- Former names
- MYnd Analytics, Inc. (until Jul 12, 2019); CNS RESPONSE, INC. (until Dec 10, 2015); STRATIVATION, INC. (until Mar 1, 2007); SalesTactix, Inc. (until Aug 23, 2005); AGE RESEARCH INC (until Aug 5, 2004)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.